Compare Dr. Reddys with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ABBOTT INDIA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ABBOTT INDIA DR. REDDYS LAB/
ABBOTT INDIA
 
P/E (TTM) x 29.0 54.8 52.9% View Chart
P/BV x 3.4 16.3 20.9% View Chart
Dividend Yield % 0.7 0.4 164.7%  

Financials

 DR. REDDYS LAB   ABBOTT INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
ABBOTT INDIA
Mar-19
DR. REDDYS LAB/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs2,8758,834 32.5%   
Low Rs1,8885,458 34.6%   
Sales per share (Unadj.) Rs930.21,731.1 53.7%  
Earnings per share (Unadj.) Rs117.4211.9 55.4%  
Cash flow per share (Unadj.) Rs185.8219.9 84.5%  
Dividends per share (Unadj.) Rs20.0065.00 30.8%  
Dividend yield (eoy) %0.80.9 92.3%  
Book value per share (Unadj.) Rs844.4945.2 89.3%  
Shares outstanding (eoy) m166.0721.25 781.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.1 62.0%   
Avg P/E ratio x20.333.7 60.1%  
P/CF ratio (eoy) x12.832.5 39.5%  
Price / Book Value ratio x2.87.6 37.3%  
Dividend payout %17.030.7 55.5%   
Avg Mkt Cap Rs m395,496151,848 260.5%   
No. of employees `00022.03.5 630.3%   
Total wages/salary Rs m33,5624,356 770.5%   
Avg. sales/employee Rs Th7,032.810,555.5 66.6%   
Avg. wages/employee Rs Th1,527.91,249.9 122.2%   
Avg. net profit/employee Rs Th887.71,292.2 68.7%   
INCOME DATA
Net Sales Rs m154,48236,786 419.9%  
Other income Rs m3,3751,133 297.9%   
Total revenues Rs m157,85737,919 416.3%   
Gross profit Rs m31,7826,047 525.6%  
Depreciation Rs m11,348169 6,706.9%   
Interest Rs m88923 3,951.1%   
Profit before tax Rs m22,9206,989 328.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8582,485 155.2%   
Profit after tax Rs m19,5004,503 433.0%  
Gross profit margin %20.616.4 125.1%  
Effective tax rate %16.835.6 47.3%   
Net profit margin %12.612.2 103.1%  
BALANCE SHEET DATA
Current assets Rs m111,10127,610 402.4%   
Current liabilities Rs m58,9738,569 688.2%   
Net working cap to sales %33.751.8 65.2%  
Current ratio x1.93.2 58.5%  
Inventory Days Days7960 131.8%  
Debtors Days Days9427 343.8%  
Net fixed assets Rs m101,2451,057 9,579.5%   
Share capital Rs m830213 390.6%   
"Free" reserves Rs m139,40619,873 701.5%   
Net worth Rs m140,23620,086 698.2%   
Long term debt Rs m22,0000-   
Total assets Rs m224,65629,409 763.9%  
Interest coverage x26.8311.6 8.6%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.71.3 55.0%   
Return on assets %9.115.4 59.0%  
Return on equity %13.922.4 62.0%  
Return on capital %14.934.9 42.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,673369 24,033.2%   
Fx outflow Rs m19,1044,918 388.4%   
Net fx Rs m69,569-4,549 -1,529.2%   
CASH FLOW
From Operations Rs m28,7044,991 575.1%  
From Investments Rs m-7,727-2,570 300.7%  
From Financial Activity Rs m-21,326-1,428 1,493.4%  
Net Cashflow Rs m-314993 -31.6%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.4 7.9 68.4%  
FIIs % 35.3 0.1 35,300.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.1 89.5%  
Shareholders   75,885 18,270 415.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Volatility, RBI Policy Meet Takeaways, and Top Cues in Focus Today(Pre-Open)

It was a volatile day for India share markets on Friday. The benchmark indices opened higher but turned volatile.

Related Views on News

BLUE DART EXPRESS Surges by 0%; BSE 500 Index Down 3.1% (Market Updates)

Mar 30, 2020 | Updated on Mar 30, 2020

BLUE DART EXPRESS share price has surged by 0% and its current market price is Rs 2,216. The BSE 500 is down by 3.1%. The top gainers in the BSE 500 Index are BLUE DART EXPRESS (down 0.2%) and ABBOTT INDIA (up 13.6%). The top losers are SKF INDIA and BLUE DART EXPRESS (down 0.2%).

CEAT LTD. Surges by 11%; BSE 500 Index Down 2.9% (Market Updates)

Mar 30, 2020 | Updated on Mar 30, 2020

CEAT LTD. share price has surged by 11% and its current market price is Rs 748. The BSE 500 is down by 2.9%. The top gainers in the BSE 500 Index are CEAT LTD. (up 11.2%) and ABBOTT INDIA (up 14.7%). The top losers are SKF INDIA and IPCA LABS .

ABBOTT INDIA Surges by 15%; BSE HEALTHCARE Index Down 0.9% (Market Updates)

Mar 30, 2020 | Updated on Mar 30, 2020

ABBOTT INDIA share price has surged by 15% and its current market price is Rs 16,211. The BSE HEALTHCARE is down by 0.9%. The top gainers in the BSE HEALTHCARE Index are ABBOTT INDIA (up 14.7%) and AJANTA PHARMA (up 6.2%). The top losers are IPCA LABS and PFIZER (down 0.2%).

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 30, 2020 09:23 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS